Cytek Biosciences Dividends and Buybacks
Dividend criteria checks 0/6
Cytek Biosciences does not have a record of paying a dividend.
Key information
n/a
Dividend yield
5.6%
Buyback Yield
Total Shareholder Yield | 5.6% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?
Dec 16Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump
Nov 07Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
Sep 13An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Aug 09Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Jul 12Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
Jun 04Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Mar 20Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals
Mar 08Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments
Jul 27Checking In On Cytek Biosciences
Mar 23Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if CTKB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTKB's dividend payments have been increasing.
Dividend Yield vs Market
Cytek Biosciences Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (CTKB) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.4% |
Industry Average (Life Sciences) | 0.5% |
Analyst forecast (CTKB) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate CTKB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTKB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate CTKB's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CTKB has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/18 23:20 |
End of Day Share Price | 2024/12/18 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cytek Biosciences, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kyle Mikson | Canaccord Genuity |
Matthew Sykes | Goldman Sachs |
Tejas Savant | Morgan Stanley |